Innoviva's shift to specialty therapeutics is backed by strong financials and a robust pipeline. Read why INVA stock presents ...

Breo brought in £41 million in the first three months of the year, while Anoro added another £12 million, unable to offset the approximately £100 million reduction in Seretide/Advair sales in ...

ACPN Laments Poor Implementation Of Zero Duty On Drugs The surge in the cost of critical drugs for treatment and managing BP ...

After hours: February 25 at 4:20:00 PM EST Loading Chart for INVA ...